Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 21
Japan's GLP-1 treatment cap and regain
A prospective Japanese cohort tracked weight before, during and after time-limited semaglutide or tirzepatide treatment.
GLP-1 Weight-Loss Drugs: Trial Review
A 24-trial network meta-analysis ranked obesity medicines, but high heterogeneity and indirect comparisons limit claims of superiority.
Nerve risks after weight loss drugs
A 2026 review links rare peripheral nerve problems with rapid weight loss during semaglutide or tirzepatide treatment.
MASH Trials: Resmetirom and Semaglutide
Two phase 3 trials support resmetirom and semaglutide in MASH, but their separate designs do not establish which treatment works better.
Semaglutide and Smoking in HIV
A cohort study linked semaglutide initiation to lower cigarette use among people with HIV, but it cannot show that the medicine caused the change.
Tirzepatide Injection Route Error
A single tirzepatide case report links accidental intradermal injection with increased adverse events, but cannot measure the risk.
Tirzepatide and TLR2 Inflammation in Mice
A mouse and cell study found tirzepatide reduced selected inflammatory responses after a Western diet. It was not a clinical outcomes trial.
Adolescent GLP 1s: The Muscle Gap
A new perspective uses semaglutide trial data to ask how adolescent GLP 1 care should track muscle, bone, and physical function.
Atypical anorexia after weight loss
A case report links severe restriction after sleeve gastrectomy, semaglutide, and tirzepatide with atypical anorexia nervosa.
Digital tirzepatide care study
A UK study of 8,127 women reported six-month outcomes from a structured digital programme where 99.8% started tirzepatide.
What Exit Interviews Add to GLP-1 Trials
A study from ACHIEVE-3 shows what exit interviews can add to oral GLP-1 trial results, and what they cannot answer.
GLP-1 Drugs and Alzheimer's: The Evidence
A 2026 meta-analysis found no cognitive or functional benefit from GLP-1 receptor agonists in Alzheimer's disease or mild cognitive impairment.